Join
Live feed
·
INSIDERFilingvia Quantisnow
Dyne Therapeutics Inc. logo

Chief Commercial Officer Friedl-Naderer Johanna sold $5,939 worth of shares (226 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 153,982 units (SEC Form 4) to satisfy withholding tax

ByQuantisnow·Wall Street's wire, on your screen.
DYN· Dyne Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.